Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Taro Pharm Inds (TARO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 4,672,423
  • Shares Outstanding, K 40,510
  • Annual Sales, $ 879,390 K
  • Annual Income, $ 456,360 K
  • 36-Month Beta 0.65
  • Price/Sales 5.31
  • Price/Cash Flow 9.89
  • Price/Book 2.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.22 +4.71%
on 06/29/17
116.80 -1.19%
on 07/05/17
-0.75 (-0.64%)
since 06/27/17
3-Month
102.52 +12.58%
on 05/30/17
118.38 -2.50%
on 05/02/17
-1.08 (-0.93%)
since 04/27/17
52-Week
92.28 +25.07%
on 11/03/16
146.89 -21.43%
on 08/08/16
-22.44 (-16.27%)
since 07/27/16

Most Recent Stories

More News
Global Mouth Ulcer Market 2017-2021 - Key vendors are Blistex, Church & Dwight, Novartis Pharmaceuticals & Valeant Pharmaceuticals

Research and Markets has announced the addition of the "Global Mouth Ulcer Market 2017-2021" report to their offering. The analysts forecast the global mouth ulcer market to grow at a CAGR of 4.31% during...

HSIC : 183.36 (-0.75%)
NVS : 84.82 (-0.04%)
TARO : 115.42 (+0.07%)
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, "Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission...

TARO : 115.42 (+0.07%)
Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR Development and Marketing in the U.S.

Research Desk Line-up: Taro Pharma Post Earnings Coverage

DRRX : 1.84 (-1.60%)
NVS : 84.82 (-0.04%)
TARO : 115.42 (+0.07%)
Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the fiscal year ended March 31, 2017, on Monday, May 22, 2017.

TARO : 115.42 (+0.07%)
Taro Provides Results for December 31, 2016

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine months ended December 31, 2016.

TARO : 115.42 (+0.07%)
Taro to Announce Third Quarter Results on February 9, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2016, after the close of...

TARO : 115.42 (+0.07%)
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque...

ENZ : 11.32 (+0.27%)
TARO : 115.42 (+0.07%)
PRGO : 74.60 (-2.15%)
BIIB : 290.34 (-1.78%)
December 27 Deadline Alert: Law Offices of Howard G. Smith Reminds Taro Pharmaceutical Industries Ltd. Investors of Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming December 27, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class")...

TARO : 115.42 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Support & Resistance

2nd Resistance Point 116.89
1st Resistance Point 116.11
Last Price 115.42
1st Support Level 114.59
2nd Support Level 113.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.